drugset / Trial / NCT01089569

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NCT01089569

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to compare the effect on 24-hour blood glucose patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a combination of insulin glargine and exenatide to metformin.

Timeline

Start
2010-04
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exenatide Peptide 10 ug
Comparator insulin glargine Protein / enzyme biologic 0.1 iu/kg